- Dementia drugs hailed as 'beginning of the end' for Alzheimer's do not work, major report finds Daily Mail —
- 'Breakthrough' Alzheimer's drugs unlikely to benefit patients, report suggests BBC News —
- Much-hyped Alzheimer’s drugs do not help patients, review finds The Straits Times —
- Alzheimer’s drugs ‘make no meaningful difference to patients,’ major review suggests The Independent —
- Alzheimer’s drugs targeting amyloid don’t help, review finds The Japan Times —
- Effect of ‘gamechanger’ Alzheimer’s drugs ‘trivial’, review concludes The Guardian —
- Analysis of Alzheimer’s Drugs Stirs Debate About Their Effectiveness The New York Times —
- Alzheimer’s drugs ‘make no meaningful difference to patients’, say researchers Belfast Telegraph —
- Alzheimer’s bombshell as top scientists conclude - ‘the drugs don’t work’ Mirror —
- Alzheimer's drugs make 'no meaningful difference' RTE —
- Alzheimer’s drugs ‘make no meaningful difference to patients’, say researchers The Standard —
- Alzheimer's 'wonder drugs' do not work, major study finds despite hopes of end to disease LBC —
- New Alzheimer’s drugs make ‘no meaningful difference’ to patients The Times —
- What’s the deal with Alzheimer’s disease and amyloid? Ars Technica —
Lecanemab
Monoclonal antibody
Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. Lecanemab is an amyloid beta-directed antibody. It is given via intravenous infusion or subcutaneous injection to people with mild cognitive impairment or mild dementia. In clinical trials, it demonstrated modest efficacy in reducing relative cognitive decline compared to placebo. The most common side effects of lecanemab include headache, infusion-related reactions, and amyloid-related imaging abnormalities, a side effect known to occur with the class of antibodies targeting amyloid. Lecanemab was jointly developed by Eisai, Biogen, and Bioarctic.
Also known as...
BAN2401, Rechembi, and Leqembi
Alzheimer's Drugs Benefits Labeled 'Trivial'